Most of what you've heard about GLP-1s online is either outdated, oversimplified, or flatly wrong.
Semaglutide and tirzepatide are among the most heavily studied medications in modern medicine — over 100,000 trial participants across the STEP, SURMOUNT, and SELECT programs alone. Yet the myths keep circulating: that they're "cheating," that you'll balloon back up the moment you stop, that they cause cancer, that compounded versions are all the same.
Below, we walk through the 15 myths we hear most often from patients considering treatment at compounded semaglutide ($197/month) or compounded tirzepatide ($297/month), and what the actual research says about each one.
If you've spent any time researching weight loss medication, you've run into conflicting information. One post says GLP-1s "melt fat" with zero effort. Another warns they'll destroy your metabolism or land you in the hospital. A third insists they're just another fad that'll be gone in a year. None of that is particularly useful when you're trying to make an actual medical decision.
GLP-1 receptor agonists — the drug class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — aren't new. The first GLP-1 medication, exenatide, was FDA-approved in 2005. What's new is the scale of public interest, and with it, the volume of misinformation. Below, we separate what the clinical trial data actually shows from what's circulating on social media.
Why GLP-1 Myths Spread So Easily
Part of the problem is speed. Semaglutide and tirzepatide went from niche diabetes drugs to some of the most talked-about medications in the country in the span of about three years, and the science communication didn't keep pace with the cultural conversation. Celebrity anecdotes, before-and-after photos, and TikTok explainers filled the gap left by slower, more careful clinical reporting — and anecdote travels faster than data.
There's also a real information gap between what the FDA's boxed warning says and what people assume it means. A warning about a rare rodent tumor becomes "GLP-1s cause cancer." A statement that weight regain is common after stopping becomes "you'll gain it all back the second you stop." The nuance gets lost, and the flattened version is what spreads. Below, we've restored the nuance for the 15 myths we hear most often.
15 GLP-1 Myths, Fact-Checked
Myth #1: "GLP-1s are the lazy way to lose weight"
What the research shows: Obesity is classified as a chronic disease involving hormonal signaling, genetics, and brain chemistry — not a simple failure of willpower. GLP-1 medications work by mimicking a naturally occurring gut hormone that regulates appetite and satiety, addressing a biological mechanism that diet and exercise alone often can't override. In the landmark STEP 1 trial, participants still followed a structured lifestyle intervention alongside medication — the drug didn't replace effort, it made the effort more effective.
Myth #2: "You'll gain all the weight back the moment you stop"
What the research shows: This one has a kernel of truth, but the "moment you stop" framing is misleading. The STEP 1 trial extension found that participants regained an average of 11.6 percentage points of the weight they'd lost within a year of stopping semaglutide — but that regain happened gradually over that year, not overnight, and roughly a third of participants maintained most of their loss. Obesity is a chronic condition; stopping treatment without a maintenance plan behaves the way stopping treatment for any chronic condition does.
Myth #3: "GLP-1s are just appetite suppressants"
What the research shows: Appetite reduction is one mechanism among several. GLP-1 receptor agonists also slow gastric emptying (which extends satiety), improve insulin sensitivity, reduce inflammatory markers, and — per the SELECT cardiovascular outcomes trial — measurably reduce cardiovascular events independent of weight loss alone. Calling them "appetite suppressants" undersells what's actually a multi-system metabolic intervention.
Myth #4: "GLP-1s destroy your metabolism"
What the research shows: Some reduction in resting metabolic rate accompanies any significant weight loss — it's called adaptive thermogenesis, and it happens with diet-only weight loss too. It isn't unique to GLP-1s, and it isn't evidence of metabolic "damage." Clinical trial data instead shows improvements in the metabolic markers that actually matter long-term: insulin sensitivity, blood glucose regulation, and lipid profiles.
Myth #5: "You can't eat carbs, sugar, or anything fun again"
What the research shows: There's no official "GLP-1 diet" and no food group you're required to eliminate. Appetite is reduced, not eliminated, and portions typically shrink naturally. Many patients find that heavier, greasy meals sit less comfortably than before — that's the slowed gastric emptying at work — but nothing is off-limits by prescription. Prioritizing protein in smaller portions tends to produce the best outcomes, not eliminating entire food categories.
Myth #6: "GLP-1s cause cancer"
What the research shows: This myth traces back to a rodent study showing thyroid C-cell tumors in mice given GLP-1 medications, which is why the FDA requires a boxed warning about medullary thyroid carcinoma (MTC). But a large Scandinavian cohort study tracking over 145,000 GLP-1 users found no increased risk of thyroid cancer compared with an alternative diabetes drug, over a mean follow-up of nearly four years. The rodent signal has not translated to human populations. Patients with a personal or family history of MTC or MEN2 syndrome should still avoid these medications — that exclusion is real and important.
Myth #7: "GLP-1s are addictive"
What the research shows: GLP-1 receptor agonists don't trigger the dopaminergic reward-pathway activation associated with addictive substances, and there's no physical withdrawal syndrome when patients stop. What does happen is that appetite signals return toward baseline — which is a pharmacological effect wearing off, not withdrawal. Needing ongoing treatment for a chronic disease isn't the same thing as dependency.
Myth #8: "All compounded GLP-1s are the same as brand-name"
What the research shows: Quality varies significantly across compounding pharmacies, which is exactly why sourcing matters. Legitimate compounded semaglutide and tirzepatide are prepared per individual prescription by state-licensed 503A pharmacies operating under USP <797> sterile-compounding standards — not mass-produced, and not interchangeable with unregulated gray-market products sold without a prescription. The active ingredient is the same molecule found in Ozempic, Wegovy, Mounjaro, and Zepbound; the pharmacy's licensing and process determine everything else.
Myth #9: "Everyone loses the same amount of weight on GLP-1s"
What the research shows: Individual response varies substantially. In SURMOUNT-1, tirzepatide produced average weight loss ranging from 16.0% to 22.5% depending on dose, with roughly 90% of participants losing weight — but "average" means real variation above and below that number. Genetics, starting weight, dose, adherence, sleep, and lifestyle factors all shape individual outcomes. Trial averages describe a population, not a guarantee for any one person.
Myth #10: "GLP-1s only work for people who are very overweight"
What the research shows: FDA-approved eligibility criteria are BMI ≥30, or BMI ≥27 with a weight-related condition such as hypertension or type 2 diabetes — but the health benefits scale meaningfully even at the lower end of that range. A 5–10% reduction in body weight measurably improves blood pressure, blood sugar, and lipid markers, well before someone reaches a dramatic transformation.
Myth #11: "GLP-1s cause pancreatitis in most patients"
What the research shows: Pancreatitis is listed as a rare potential adverse event in prescribing information, but large-scale trial and real-world data have not shown meaningfully increased rates compared with the general population. Patients with a personal history of pancreatitis should discuss this specifically with their prescribing provider, since that history does change the risk calculation for an individual patient.
Myth #12: "You can safely buy GLP-1s online without a prescription"
What the research shows: Legitimate GLP-1 treatment requires a medical evaluation and an active prescription from a licensed provider — full stop. Products marketed online without any clinical evaluation carry real risk of being counterfeit, mis-dosed, or contaminated, since there's no licensed pharmacy or clinician verifying what's actually in the vial. Any provider that skips the medical evaluation step is a red flag, regardless of price.
Myth #13: "GLP-1s are too new to trust"
What the research shows: GLP-1 receptor agonists as a drug class have been FDA-approved since 2005, and semaglutide specifically has been on the market since 2017. The SURMOUNT and STEP clinical trial programs alone enrolled well over 100,000 participants, and the SELECT cardiovascular outcomes trial followed 17,604 patients across a multi-year study. This is not an unproven or experimental drug class — it has one of the more extensive safety datasets of any recent medication category.
Myth #14: "Insurance will never cover GLP-1s for weight loss"
What the research shows: Coverage has been expanding, not shrinking. Mercer's 2025 National Survey of Employer-Sponsored Health Plans found that 49% of large employers (500+ employees) now cover GLP-1 medications for weight management, up from 44% the year before. Coverage still isn't universal, and it varies significantly by plan — but the trend has been toward broader access. For patients whose insurance doesn't cover treatment, cash-pay compounded options remain a meaningfully lower-cost path than brand-name list price.
Myth #15: "Natural supplements work just as well as GLP-1 medications"
What the research shows: No over-the-counter supplement — berberine, apple cider vinegar, or otherwise — has produced anything close to the 15–22% average body-weight reduction seen in GLP-1 clinical trials. Supplements marketed as "natural GLP-1 boosters" are not held to the same efficacy or safety evidence standards as an FDA-regulated prescription medication, and the evidence behind most of them is thin at best.
What the trial data actually shows
Every patient starts with a real medical evaluation from a licensed provider — not a quiz that auto-approves everyone. Compounded semaglutide is $197/month and compounded tirzepatide is $297/month, flat, prepared by VialsRX, a 503A pharmacy licensed by the Texas State Board of Pharmacy (license #35264, verifiable directly with the board). See all treatment options →
Who Should Talk to a Provider First
- A personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- A history of pancreatitis
- Severe gastrointestinal disease
- Are pregnant, breastfeeding, or planning pregnancy
- Severe kidney impairment
- BMI ≥30, or BMI ≥27 with a weight-related condition
- Realistic expectations about gradual, sustained weight loss
- Willingness to pair treatment with basic lifestyle changes
- No contraindicating personal or family medical history
- Interest in ongoing provider monitoring, not a one-time prescription
Ready to get the facts,
not the myths?
Physician-evaluated compounded semaglutide from $197/month and tirzepatide from $297/month. Real medical evaluation, ongoing provider support, and free shipping — no guesswork.
Get Started → Or start your free health assessmentFrequently Asked Questions
No. Obesity is recognized as a chronic disease by the AMA, WHO, and every major medical organization. GLP-1 medications also provide measurable cardiovascular protection (per the SELECT trial), improve type 2 diabetes management, and can reduce obstructive sleep apnea severity. Treating obesity is medical care, not a cosmetic pursuit.
They produce weight loss even without an intensive structured lifestyle program, but results are consistently better when combined with adequate protein intake and regular movement. The medication addresses the biological barriers — appetite and hormonal signaling — while lifestyle habits provide the structural support for lasting results.
GLP-1 receptor agonists have been used to treat type 2 diabetes since 2005, giving clinicians nearly two decades of real-world safety data. Long-term outcome studies, including the SELECT cardiovascular trial, have shown not just an acceptable safety profile but active cardiovascular benefit. No medication is entirely risk-free, but this drug class has one of the more thoroughly studied safety records of any recent medication category.
Not necessarily. Some patients successfully transition to a lower maintenance dose, some taper off with a strong lifestyle foundation in place, and some continue long-term treatment — similar to how blood pressure or cholesterol medication is managed. The right approach depends on individual response and should be worked out with your prescribing provider.
Compounded medications contain the same active pharmaceutical ingredient as brand-name Ozempic, Wegovy, Mounjaro, and Zepbound. Effectiveness depends heavily on the compounding pharmacy's quality standards and dosing accuracy, which is why sourcing from a state-licensed 503A pharmacy with transparent oversight matters as much as the molecule itself.
Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both the GLP-1 and GIP receptors, which tends to produce somewhat greater average weight loss in clinical trials. Read our full semaglutide vs. tirzepatide comparison for a detailed breakdown.
Coverage varies by plan, but it has been expanding: about 49% of large employers now cover GLP-1s for weight management, according to Mercer's 2025 survey. If your plan doesn't cover treatment, compounded options through a licensed provider are typically far less expensive than brand-name list price out of pocket.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
- Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024;385:e078225. PMC11004669
- Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024. PubMed 38785209
- Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database